Skip to main content

Table 1 Patient characteristics of the study population in the primary analysis

From: Consolidative chemotherapy after definitive concurrent chemoradiotherapy for esophageal squamous cell carcinoma patients: a population based cohort study

 

Patient characteristics before PSW

Patient characteristics (%) after PSWa

CCT (n = 103)

Without CCT (n = 265)

Standardized differenceb

CCT

Without CCT

Standardized differenceb

Number (%)b or mean (SD)b

Number (%)b or mean (SD)b

Age (years)

      

  ≤ 58

53 (51)

139 (52)

0.020

50

50

≈ 0

  > 58

50 (49)

126 (48)

 

50

50

 

Gender

      

 Female

5 (5)

12 (5)

0.015

5

5

≈ 0

 Male

98 (95)

253 (95)

 

95

95

 

Residency

      

 Non-north

77 (75)

185 (70)

0.111

73

73

≈ 0

 North

26 (25)

80 (30)

 

27

27

 

Comorbidity

      

 Without

91 (88)

233 (88)

0.013

89

89

≈ 0

 Withc

12 (12)

32 (12)

 

11

11

 

BMI (kg/m2)

      

  ≤ 18.5

22 (21)

62 (23)

0.049

21

21

≈ 0

  > 18.5

81 (79)

203 (77)

 

79

79

 

Drinking

      

 No

14 (14)

46 (17)

0.104

14

14

≈ 0

 Yes

89 (86)

219 (83)

 

86

86

 

Smoking

      

 No

10 (10)

43 (16)

0.195

11

11

≈ 0

 Yes

93 (90)

222 (84)

 

89

89

 

Grade

      

 Poorly

34 (33)

59 (22)

0.242

30

30

≈ 0

 Well/moderately differentiated

69 (67)

206 (78)

 

70

70

 

Tumor location

      

 Upper

56 (54)

97 (37)

 

50

50

 

 Middle

34 (33)

122 (46)

0.269

36

36

≈ 0

 Lower

13 (13)

46 (17)

0.133

14

14

≈ 0

Tumor size (cm)

      

  ≤ 5 cm

43 (42)

99 (37)

0.090

41

41

≈ 0

  > 5 cm

60 (58)

166 (63)

 

59

59

 

Clinical T-stage

      

 T1–T2

10 (10)

32 (12)

0.076

10

10

≈ 0

 T3–T4

93 (90)

233 (88)

 

90

90

 

Clinical N-stage

      

 N0

9 (9)

23 (9)

0.002

9

9

≈ 0

 N1-N2

94 (91)

242 (91)

 

91

91

 

Clinical stage

      

 II

11 (11)

30 (11)

0.020

12

12

≈ 0

 III

92 (89)

235 (89)

 

88

88

 

Reason for no surgery

      

 Without contraindication

99 (96)

248 (94)

0.115

95

95

≈ 0

 With contraindication

4 (4)

17 (6)

 

5

5

 

RT modality

      

 3DCRT

7 (7)

7 (3)

0.197

5

5

≈ 0

 IMRT

96 (93)

258 (97)

 

95

95

 

Use of PET

      

 No

45 (44)

77 (29)

0.308

37

37

≈ 0

 Yes

58 (56)

188 (71)

 

63

63

 

RT break

      

  ≤ 1 week

79 (77)

197 (74)

0.055

76

76

≈ 0

  > 1 week

24 (23)

68 (26)

 

24

24

 

RT dose

      

 Low

25 (24)

88 (33)

0.198

26

26

≈ 0

 High

78 (76)

177 (67)

 

74

74

 

Induction chemotherapy

      

 Without

98 (95)

258 (97)

0.117

96

96

≈ 0

 With

5 (5)

7 (3)

 

4

4

 
  1. 3DCRT, three-dimensional radiotherapy; BMI, Body Mass Index; CCT, consolidative chemotherapy; IGRT, image-guided radiotherapy; IMRT, intensity-modulated radiotherapy; PET, positron emission tomography; PSW, Propensity Score (PS) Weighting; RT, radiotherapy; SD, standard deviation
  2. aWeighted proportion for each group
  3. bRounded
  4. cModified Carlson comorbidity score ≥ 1